ABT
New target, same thumbs-up
Abbott got a fresh haircut from Citigroup, which dropped its price target to $108 from $136 while leaving the Buy rating untouched. So no, this isn’t a full breakup — just a slightly less enthusiastic valuation haircut after the stock’s latest run and the company’s recent update.
What that means for your portfolio
A lower target can matter even when the rating stays bullish. It usually tells you the analyst still likes the business but sees less room for the stock to sprint higher from here. In plain English: the runway got shorter, not the plane.
Why investors should care
Abbott has been a market favorite in the med-tech lane, but the Street is clearly recalibrating after the company’s latest news cycle. When multiple analysts start shaving targets around the same time, it can signal that expectations were a little too sunny and everyone’s now reaching for the umbrella.
Big picture
This isn’t a red flag screaming “sell.” It’s more like the analyst version of lowering your karaoke volume after realizing the neighbors are home. Still constructive, just less exuberant.